# Spain Anti VEGF Market > Spain Anti-VEGF Market Research Report: Size, Share, Trend Analysis By Product (Eylea, Lucentis, Beovu) andBy Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-Related Macular Degeneration) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.31% - **2024:** $ 389.76 Million - **2025:** $ 406.56 Million - **2035:** $ 620.12 Million - **Key Players:** Regeneron Pharmaceuticals (US), Roche Holding (CH), Novartis AG (CH), Bayer AG (DE), Pfizer Inc. (US), Amgen Inc. (US), Eli Lilly and Company (US), Santen Pharmaceutical Co. Ltd. (JP) **Report ID:** MRFR/HC/50416-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/spain-anti-vegf-market-52174 --- ## Market Summary ## **Spain Anti-VEGF Market Overview:** As per MRFR analysis, the Spain Anti-VEGF Market Size was estimated at 697.45 (USD Million) in 2023. The Spain Anti-VEGF Market Industry is expected to grow from 727.44(USD Million) in 2024 to 1,034.36 (USD Million) by 2035. The Spain Anti-VEGF Market CAGR (growth rate) is expected to be around 3.252% during the forecast period (2025 - 2035). ### **Key Spain Anti-VEGF Market Trends Highlighted** A combination of demographic and healthcare advancements in the Spain Anti-VEGF Market is driving significant changes. The increasing prevalence of age-related macular degeneration (AMD) and diabetic retinopathy, which are among the most significant causes of vision loss in the geriatric population, is one of the primary market drivers. Healthcare policies are being influenced by the ageing demographic, which is urging them to prioritize the development of effective treatments for ocular diseases. Furthermore, the patient population that is interested in Anti-VEGF therapies is expanding as a result of the growing public awareness and education about retinal disorders. The Spanish market offers opportunities for the development of biosimilar medications, which can reduce treatment costs and increase competition. The Spanish healthcare system promotes innovation by promoting collaborations between pharmaceutical companies and research institutions, which can result in the development of novel therapeutic options. Additionally, there is a growing emphasis on personalised medicine, which is designed to meet the unique requirements of each patient, thereby facilitating superior treatment outcomes. In recent years, the Anti-VEGF market in Spain has been significantly influenced by advancements in drug delivery systems. Sustained-release formulations have gained popularity as a result of their potential to enhance patient compliance. Healthcare professionals are increasingly incorporating these new technologies into their practices, as they have the potential to result in more effective therapies with extended treatment intervals. The integration of telemedicine in ophthalmology is also garnering attention, as it enables remote monitoring and consultations, which enables timely interventions for patients with retinal diseases. In general, the Anti-VEGF market in Spain is characterised by a dynamic and ever-changing landscape that is influenced by both opportunities and challenges for stakeholders. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **Spain Anti-VEGF Market Drivers** ### Increasing Incidence of Retinal Diseases Spain has seen a rise in the incidence of age-related macular degeneration (AMD) and diabetic retinopathy, which are significant contributors to visual impairment and blindness in the aging population. Reports indicate that the number of individuals affected by AMD is expected to increase by over 25% in the next decade, emphasizing the need for effective treatment solutions. The Spanish Society of Ophthalmology has noted a growing awareness and diagnosis of these conditions, which contributes to the demand for Anti-vascular Endothelial Growth Factor (Anti-VEGF) therapies.With over 1.3 million people in Spain currently diagnosed with AMD, the market for Anti-VEGF medications vitalizes the Spain Anti-VEGF Market Industry as healthcare providers aim to improve patient outcomes through novel treatments. ### Advancements in Treatment Modalities The introduction of novel Anti-VEGF therapies and biosimilars is transforming the Spain Anti-VEGF Market Industry. Innovative therapies are continuously being developed, aimed at improving efficacy and reducing side effects. According to industry reports, the availability of biosimilars is expected to decrease treatment costs significantly, making therapies more accessible to a broader patient population. Established organizations like the Spanish Agency of Medicines and Medical Devices (AEMPS) have been proactive in approving these new treatment options, which will likely drive market growth by providing patients with more cost-effective alternatives. ### Government Initiatives and Healthcare Funding The Spanish government has made substantial investments in healthcare, particularly in the ophthalmology sector, through funding initiatives like the National Health System (SNS). This increased funding aims to improve the management of chronic eye diseases among the population. Additionally, the implementation of public health programs focused on screening and early detection of retinal diseases has heightened awareness and treatment uptake. Such initiatives are essential for the growth of the Spain Anti-VEGF Market, as timely intervention can lead to better patient outcomes and increased demand for Anti-VEGF treatments. ### Aging Population and Growing Healthcare Needs Spain's demographic trends show an increasing aging population, with projections indicating that over 25% of the population will be aged 65 and older by 2035. This age group is particularly susceptible to eye diseases that necessitate Anti-VEGF treatment. The Spanish Ministry of Health has noted a direct relationship between aging and the prevalence of visual disorders, which in turn influences the demand for effective treatments. As healthcare providers cater to the growing needs of an elderly population, the Spain Anti-VEGF Market Industry is positioned for substantial growth, necessitating more extensive healthcare resources to manage and treat age-related ocular conditions. ## **Spain Anti-VEGF Market Segment Insights** ### **Anti-VEGF Market Product Insights** The Spain Anti-VEGF Market for products plays a significant role in the evolving landscape of ophthalmic therapies, particularly for conditions such as age-related macular degeneration and diabetic retinopathy. A variety of products are present within this segment, which are designed to inhibit vascular endothelial growth factor, effectively reducing the progression of these retinal diseases. Eylea has emerged as a key player, praised for its long duration of action and favorable dosing schedule, which has made it a popular choice among healthcare providers in Spain. Another product, Lucentis, has established itself over the years with strong clinical efficacy and extensive use in treatment protocols, reflecting its dominance in therapeutic practices. Beovu, although relatively newer, has garnered attention for its unique formulation and convenience, offering possibilities for extended treatment intervals. The complex dynamics in the Spain Anti-VEGF Market segmentation show that while there is healthy competition among these products, their distinct characteristics contribute to different patient needs and preferences Various factors drive the growth in this segment, including the increasing prevalence of retinal diseases, advancements in drug formulation, and a robust healthcare infrastructure that supports innovative therapies. Moreover, the strong emphasis on Research and Development in Spain can be seen as a critical driver for the adoption of these products, with many clinical trials underway to explore their efficacy and safety further. This scenario showcases an environment that fosters innovation and meets an essential need in ophthalmic care, presenting numerous opportunities for stakeholders in the market.Overall, the Product segment of the Spain Anti-VEGF Market indicates a landscape that is vibrant and essential, underscoring the importance of emerging therapies in improving patient outcomes and addressing significant public health challenges. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **Anti-VEGF Market Disease Insights** The Spain Anti-VEGF Market, focused on the Disease segment, plays a crucial role in addressing various ocular conditions that affect a significant portion of the population. Macular Edema represents a major cause of vision loss in individuals with diabetes, and consistent treatment is essential to manage its progression effectively. Diabetic Retinopathy is another pressing issue, as it continues to rise alongside the increasing prevalence of diabetes in Spain, necessitating efficient solutions. Also, Retinal Vein Occlusion contributes to visual impairment, highlighting the importance of proactive treatment options in ophthalmic practices.Age-Related Macular Degeneration remains a dominant condition impacting older adults, driving innovations and research in Anti-VEGF therapies. The amalgamation of these factors makes the Disease segment of the Spain Anti-VEGF Market critical for improving public health outcomes and providing economic opportunities within the healthcare sector. The evolving landscape requires healthcare professionals to stay updated on treatment advancements to combat these pressing ocular challenges effectively, ensuring a better quality of life for the affected demographic across Spain. ## **Spain Anti-VEGF Market Key Players and Competitive Insights:** The Spain Anti-VEGF Market has been witnessing substantial growth, driven by increasing awareness of retinal diseases and the corresponding healthcare needs of the population. Anti-VEGF therapies are crucial in treating conditions like age-related macular degeneration and diabetic retinopathy, contributing significantly to the landscape of vision-related healthcare. The competitive environment within this market is shaped by various factors, including advancements in drug formulations, distribution channels, and partnerships between pharmaceutical companies and healthcare providers. Additionally, regulatory trends, market penetration strategies, and stakeholders' collaboration influence the overall dynamics of the landscape. Companies strive to innovate and differentiate their product offerings to capture market share while addressing the ongoing challenges in treatment accessibility and affordability.Within the Spain Anti-VEGF Market, Eisai has established a notable presence characterized by its commitment to neurological and oncology therapeutic areas. The company's strengths lie in its innovative research-driven approach and strategic focus on patient-centric solutions. Eisai leverages its extensive experience in the pharmaceutical industry to offer effective anti-VEGF treatments, catering to the specific needs of the Spanish population suffering from retinal disorders. Furthermore, Eisai emphasizes collaboration with healthcare professionals to enhance clinical outcomes and ensure that patients receive effective therapies in a timely manner. The company's local operations are reinforced by its robust clinical research initiatives designed to gather real-world evidence, thus solidifying its reputation in Spain's competitive landscape.Regeneron Pharmaceuticals plays a pivotal role in the Spain Anti-VEGF Market, primarily recognized for its flagship product, which has revolutionized the treatment of various retinal diseases. The company's strong presence is bolstered by its commitment to innovative research and development, aiming to improve patient access to high-quality treatments. Regeneron’s strengths stem from its cutting-edge technology and comprehensive scientific studies, which contribute to enhancing therapeutic efficacy. To further strengthen its market position, Regeneron has engaged in strategic partnerships and collaborations that focus on advancing treatment modalities specifically tailored for the Spanish healthcare system. The company has also pursued mergers and acquisitions to augment its portfolio, enabling it to strengthen its competitive edge within Spain. By actively investing in local healthcare initiatives and building relationships with ophthalmologists and healthcare institutions, Regeneron continues to solidify its reputation as a key player in the anti-VEGF market in Spain. ### **Key Companies in the Spain Anti-VEGF Market Include:** ## **Spain Anti-VEGF Market Industry Developments** The Spain Anti-VEGF market has recently seen significant developments. Noteworthy is the continued growth of companies like Novartis, Regeneron Pharmaceuticals, and Roche, driven by increased demand for treatments related to age-related macular degeneration and diabetic eye diseases. The market valuation has reportedly surged, fueled by advancements in Research and Development and expanded access to therapies. In June 2023, Bayer announced collaboration with Santen Pharmaceutical to enhance ophthalmic drug development, which is likely to strengthen their positions in the Spanish market. Meanwhile, in April 2023, AbbVie made headlines by acquiring a smaller biotech firm specialized in ocular diseases, a move enhancing its portfolio in the anti-VEGF space. The Spanish government's push towards innovation and its investment in healthcare have positioned the country as a burgeoning hub for pharmaceutical advancements. There have been notable increases in funding for clinical trials and Research and Development projects, fostering an environment for new treatment options to emerge, directly benefiting patients. Additionally, Merck and Amgen continue to explore partnerships at the regional level to further tap into the growing demand for effective treatments in Spain. ## **Spain Anti-VEGF Market Segmentation Insights** ### **Anti-VEGF Market Product****Outlook** ### **Anti-VEGF Market Disease****Outlook** ## Market Drivers ### Increasing Aging Population The anti-VEGF market in Spain is experiencing growth due to the increasing aging population. As individuals age, the prevalence of age-related macular degeneration and other retinal diseases rises significantly. In Spain, approximately 19% of the population is aged 65 and older, which correlates with a higher incidence of these conditions. This demographic shift is likely to drive demand for anti-VEGF therapies, as healthcare providers seek effective treatments to manage these diseases. The anti vegf market must adapt to this demographic trend by ensuring accessibility and affordability of treatments for older patients, potentially leading to increased healthcare expenditures. Furthermore, the aging population may necessitate more comprehensive healthcare policies that support the development and distribution of anti-VEGF therapies, thereby enhancing the overall market landscape. ### Rising Healthcare Expenditure In Spain, rising healthcare expenditure is a crucial driver for the anti vegf market. The Spanish government has been increasing its healthcare budget, which is projected to reach approximately €130 billion by 2026. This increase in funding is likely to enhance access to innovative treatments, including anti-VEGF therapies, for patients suffering from retinal diseases. The anti vegf market stands to gain from this trend, as more resources become available for the procurement of advanced therapies. Additionally, as healthcare spending rises, there may be a greater emphasis on preventive care and early intervention, which could further boost the demand for anti-VEGF treatments. The market's growth potential appears promising, given the supportive financial environment that encourages the development and distribution of these essential therapies. ### Supportive Clinical Guidelines Supportive clinical guidelines play a pivotal role in shaping the anti vegf market in Spain. The endorsement of anti-VEGF therapies by leading ophthalmology associations and health authorities encourages their use in clinical practice. These guidelines often recommend timely intervention for patients with retinal diseases, which can lead to increased prescriptions of anti-VEGF treatments. The anti vegf market is likely to benefit from this supportive framework, as healthcare professionals are more inclined to adopt evidence-based practices that align with established guidelines. Additionally, as new clinical data emerges, these guidelines may evolve, further influencing treatment protocols and market dynamics. The alignment of clinical practice with robust guidelines is essential for the sustained growth of the anti vegf market, ensuring that patients receive optimal care. ### Growing Awareness of Eye Health The anti vegf market in Spain is benefiting from a growing awareness of eye health among the general population. Public health campaigns and educational initiatives are increasingly emphasizing the importance of regular eye examinations and early detection of retinal diseases. This heightened awareness is likely to lead to more individuals seeking medical attention for symptoms related to age-related macular degeneration and diabetic retinopathy. Consequently, the anti vegf market may experience increased demand for treatments as more patients are diagnosed and treated. Furthermore, healthcare providers are becoming more proactive in screening at-risk populations, which could further drive the utilization of anti-VEGF therapies. As awareness continues to grow, the anti vegf market must ensure that effective treatment options are readily available to meet the rising demand. ### Advancements in Medical Technology Technological advancements in the field of ophthalmology are significantly impacting the anti vegf market in Spain. Innovations such as improved imaging techniques and minimally invasive surgical procedures enhance the diagnosis and treatment of retinal diseases. For instance, the introduction of optical coherence tomography (OCT) allows for better visualization of retinal structures, facilitating timely intervention with anti-VEGF therapies. The anti vegf market is likely to benefit from these advancements, as they can lead to improved patient outcomes and increased adoption of these therapies. Moreover, the integration of artificial intelligence in diagnostic processes may streamline treatment protocols, further driving market growth. As technology continues to evolve, the anti vegf market must remain agile, adapting to new tools and methodologies that enhance treatment efficacy and patient care. ## Future Outlook The [Anti VEGF Market](https://www.marketresearchfuture.com/reports/anti-vegf-market-21963) in Spain is projected to grow at a 4.31% CAGR from 2025 to 2035, driven by increasing prevalence of retinal diseases and advancements in drug formulations. **New opportunities:** - Development of biosimilars to enhance market access and affordability. - Expansion of telemedicine platforms for remote patient monitoring and consultations. - Strategic partnerships with healthcare providers for integrated treatment solutions. By 2035, the anti-VEGF market is expected to solidify its position as a key segment in ophthalmic therapeutics. ## Segment Insights ### By Product: Eylea (Largest) vs. Beovu (Fastest-Growing) In the Spain anti vegf market, Eylea dominates with the largest market share among its competitors. Lucentis, while still significant, holds a smaller percentage, indicating a decline in its usage over recent years. On the other hand, Beovu is carving out its place and showing potential to capture a larger share of the market as it gains traction among healthcare providers and patients alike. The growth trends within this segment reflect an increasing preference for Eylea due to its established efficacy and favorable dosing regimen. Meanwhile, Beovu is emerging as the fastest-growing option, attributed to its innovative formulation and clinical adoption. Factors such as aging populations and rising incidences of retinal diseases contribute to the overall expansion of this segment, showcasing opportunities for growth and market penetration. Eylea (Dominant) vs. Beovu (Emerging) Eylea, recognized as the dominant player in the segment, is well-regarded for its efficacy in treating various retinal conditions. Its sustained success is linked to robust clinical data and consistent recommendation from ophthalmologists across Spain. In contrast, Beovu is emerging, leveraging its recent market entry and unique formulation that allows for fewer injections compared to traditional therapies. This has positioned Beovu favorably among patients seeking convenience and effective treatment. Lucentis, while still present, faces challenges in maintaining its relevance as newer therapies, such as Beovu, gain popularity. The dynamic between Eylea's established reputation and Beovu's innovative approach illustrates a competitive landscape, with key drivers influencing patient and provider preferences. ### By Disease: Macular Edema (Largest) vs. Diabetic Retinopathy (Fastest-Growing) In the Spain anti vegf market, Macular Edema represents the largest segment, capturing a significant market share due to its prevalence among patients suffering from various retinal conditions. This segment is primarily driven by the increasing incidence of diabetes and related eye disorders, which have heightened the demand for anti-VEGF treatments. Diabetic Retinopathy follows closely as a significant player, showcasing a robust market presence and growth potential. The growth trends in this segment are influenced by a rising aging population, along with advancements in medical technology and treatment options. The demand for early intervention and effective management of retinal diseases is on the rise, contributing to the rapid expansion of Diabetic Retinopathy treatments specifically. Innovations in drug delivery systems and the development of new therapies are expected to further fuel the growth of this segment in the coming years. Macular Edema (Dominant) vs. Diabetic Retinopathy (Emerging) Macular Edema continues to dominate the Spain anti vegf market due to its widespread recognition and established treatment protocols. This segment benefits from a well-developed understanding of the underlying pathology and proven therapeutic options. On the other hand, Diabetic Retinopathy is emerging rapidly as a significant segment, driven by increasing awareness and screening programs aimed at early detection. The surge in diabetes prevalence directly impacts the market, creating a greater need for effective anti-VEGF therapies targeting this condition. The growth dynamics are further stimulated by ongoing clinical studies validating the efficacy of new treatments, fostering competitive innovation and expanding patient access. ## Competitive Benchmarking The anti-VEGF market in Spain is characterized by a competitive landscape that is both dynamic and multifaceted. Key growth drivers include an increasing prevalence of retinal diseases, advancements in drug formulations, and a growing emphasis on personalized medicine. Major players such as Regeneron Pharmaceuticals (US), Roche Holding (CH), and Novartis AG (CH) are strategically positioned to leverage these trends. Regeneron Pharmaceuticals (US) focuses on innovation through its flagship product, Eylea, which has seen significant uptake due to its efficacy in treating various ocular conditions. Meanwhile, Roche Holding (CH) emphasizes partnerships and collaborations to enhance its research capabilities, particularly in the realm of gene therapy. Novartis AG (CH) is actively pursuing regional expansion, particularly in underserved markets, which may bolster its competitive edge in the anti-VEGF segment.The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of key players like Bayer AG (DE) and Pfizer Inc. (US) suggests a trend towards consolidation, as these companies seek to enhance their operational efficiencies and market reach. In October Bayer AG (DE) announced a strategic partnership with a leading biotechnology firm to co-develop a next-generation anti-VEGF therapy. This collaboration is poised to enhance Bayer's product pipeline and may significantly impact its market positioning by introducing innovative treatment options that could address unmet medical needs. The strategic importance of this partnership lies in its potential to accelerate the development timeline and improve patient outcomes, thereby reinforcing Bayer's commitment to innovation in the anti-VEGF space. In September Pfizer Inc. (US) launched a new digital platform aimed at improving patient access to anti-VEGF therapies. This initiative reflects a broader trend towards digital transformation within the pharmaceutical industry, as companies seek to enhance patient engagement and streamline the treatment process. The strategic significance of this move is underscored by the increasing demand for telehealth solutions, which may facilitate better adherence to treatment regimens and ultimately improve clinical outcomes. In August Novartis AG (CH) expanded its manufacturing capabilities in Spain, investing €50 million in a new facility dedicated to the production of anti-VEGF therapies. This investment not only underscores Novartis's commitment to localizing its supply chain but also positions the company to respond more effectively to regional demand fluctuations. The strategic importance of this expansion lies in its potential to enhance operational efficiency and reduce lead times, thereby improving Novartis's competitive stance in the market. As of November current competitive trends in the anti-VEGF market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaborative innovation in addressing complex healthcare challenges. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This shift may ultimately reshape the landscape of the anti-VEGF market, fostering a more sustainable and patient-centric approach to treatment. ## Recent News & Developments The Spain Anti-VEGF market has recently seen significant developments. Noteworthy is the continued growth of companies like Novartis, Regeneron Pharmaceuticals, and Roche, driven by increased demand for treatments related to age-related macular degeneration and diabetic eye diseases. The market valuation has reportedly surged, fueled by advancements in Research and Development and expanded access to therapies. In June 2023, Bayer announced collaboration with Santen Pharmaceutical to enhance ophthalmic drug development, which is likely to strengthen their positions in the Spanish market. Meanwhile, in April 2023, AbbVie made headlines by acquiring a smaller biotech firm specialized in ocular diseases, a move enhancing its portfolio in the anti-VEGF space. The Spanish government's push towards innovation and its investment in healthcare have positioned the country as a burgeoning hub for pharmaceutical advancements. There have been notable increases in funding for clinical trials and Research and Development projects, fostering an environment for new treatment options to emerge, directly benefiting patients. Additionally, Merck and Amgen continue to explore partnerships at the regional level to further tap into the growing demand for effective treatments in Spain. ## Report Scope | MARKET SIZE 2024 | 389.76(USD Million) | | --- | --- | | MARKET SIZE 2025 | 406.56(USD Million) | | MARKET SIZE 2035 | 620.12(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.31% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Regeneron Pharmaceuticals (US), Roche Holding (CH), Novartis AG (CH), Bayer AG (DE), Pfizer Inc. (US), Amgen Inc. (US), Eli Lilly and Company (US), Santen Pharmaceutical Co. Ltd. (JP) | | Segments Covered | Product, Disease | | Key Market Opportunities | Emerging therapies targeting novel pathways in the anti vegf market present significant growth potential. | | Key Market Dynamics | Rising demand for innovative anti-VEGF therapies driven by regulatory support and competitive market dynamics in Spain. | | Countries Covered | Spain | ## Frequently Asked Questions **Q: What was the overall valuation of the anti VEGF market in Spain in 2024?** A: The overall market valuation was $389.76 Million in 2024. **Q: What is the projected market valuation for the anti VEGF market in Spain by 2035?** A: The projected valuation for 2035 is $620.12 Million. **Q: What is the expected CAGR for the anti VEGF market in Spain during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 4.31%. **Q: Which product segment had the highest valuation in 2024 within the anti VEGF market?** A: Eylea had the highest valuation at $150.0 Million in 2024. **Q: What is the projected valuation for the Beovu product segment by 2035?** A: The projected valuation for Beovu by 2035 is $200.12 Million. **Q: Which disease segment is expected to show the highest growth in the anti VEGF market by 2035?** A: Age-Related Macular Degeneration is expected to show the highest growth, with a projected valuation of $210.12 Million by 2035. **Q: Who are the key players in the Spain anti VEGF market?** A: Key players include Regeneron Pharmaceuticals, Roche Holding, Novartis AG, Bayer AG, Pfizer Inc., Amgen Inc., Eli Lilly and Company, and Santen Pharmaceutical Co. Ltd. **Q: What was the valuation of the Macular Edema segment in 2024?** A: The valuation of the Macular Edema segment was $100.0 Million in 2024. **Q: How does the valuation of Diabetic Retinopathy compare to that of Retinal Vein Occlusion in 2024?** A: In 2024, Diabetic Retinopathy was valued at $90.0 Million, whereas Retinal Vein Occlusion was valued at $70.0 Million. **Q: What is the anticipated market trend for the anti VEGF market in Spain over the next decade?** A: The market is anticipated to grow steadily, reaching $620.12 Million by 2035, driven by a CAGR of 4.31%. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/spain-anti-vegf-market-52174*